MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), is pleased to share two cutting-edge research posters at the AACR 2026 Annual Meeting (April 17–22, San Diego, USA).

1.        YL413: Novel Dual-Payload Anti-HER2 ADC

• Features dual payloads (topoisomerase I inhibitor + tubulin inhibitor) built on MediLink’s tumor microenvironment cleavable mechanism

• Demonstrates robust efficacy in Enhertu-resistant and HER2-low expression tumor models

• Shows excellent stability, homogeneity, and controlled DAR, with strong potential to address resistance of current HER2 ADCs

        2.        YL252: Dual-Functional PD-L1/VEGF-Targeted ADC

• Powered by the proprietary TMALIN® platform, integrating immunotherapy, anti-angiogenesis, and cytotoxicity

• Blocks PD-1/PD-L1 and VEGF/VEGFR pathways while delivering potent tumor killing

• Favorable safety profile confirmed in non-human primate studies; supports clinical development across multiple solid tumors

MediLink continues to advance its TMALIN® technology platform, with 14 clinical-stage ADC candidates. We are committed to developing best-in-class conjugate therapies to address unmet medical needs for patients worldwide.

#AACR2026 #ADC #CancerResearch #Biotech #Innovation #MediLinkTherapeutics #Oncology